Selvakumar Subbian

Prof. Selvakumar Subbian

Public Health Research Institute at New Jersey Medical School
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
Radha GopalaswamyRadha Gopalaswamy
Radha Gopalaswamy
SSSivakumar Shanmugam
Sivakumar Shanmugam
RMRajesh Mondal
Rajesh Mondal
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
Pulmonary diseases due to mycobacteria cause significant morbidity and mortality to human health. In addition to tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), recent epidemiological studies have shown the emergence of non-tuberculous mycobacteria (NTM) species in causing lung diseases in humans. Although more than 170 NTM species are present in various environmental niches, only a handful, primarily Mycobacterium avium complex and M. abscessus, have been implicated in pulmonary disease. While TB is transmitted through inhalation of aerosol droplets containing Mtb, generated by patients with symptomatic disease, NTM disease is mostly disseminated through aerosols originated from the environment. However, following inhalation, both Mtb and NTM are phagocytosed by alveolar macrophages in the lungs. Subsequently, various immune cells are recruited from the circulation to the site of infection, which leads to granuloma formation. Although the pathophysiology of TB and NTM diseases share several fundamental cellular and molecular events, the host-susceptibility to Mtb and NTM infections are different. Striking differences also exist in the disease presentation between TB and NTM cases. While NTM disease is primarily associated with bronchiectasis, this condition is rarely a predisposing factor for TB. Similarly, in Human Immunodeficiency Virus (HIV)-infected individuals, NTM disease presents as disseminated, extrapulmonary form rather than as a miliary, pulmonary disease, which is seen in Mtb infection. The diagnostic modalities for TB, including molecular diagnosis and drug-susceptibility testing (DST), are more advanced and possess a higher rate of sensitivity and specificity, compared to the tools available for NTM infections. In general, drug-sensitive TB is effectively treated with a standard multi-drug regimen containing well-defined first- and second-line antibiotics. However, the treatment of drug-resistant TB requires the additional, newer class of antibiotics in combination with or without the first and second-line drugs. In contrast, the NTM species display significant heterogeneity in their susceptibility to standard anti-TB drugs. Thus, the treatment for NTM diseases usually involves the use of macrolides and injectable aminoglycosides. Although well-established international guidelines are available, treatment of NTM disease is mostly empirical and not entirely successful. In general, the treatment duration is much longer for NTM diseases, compared to TB, and resection surgery of affected organ(s) is part of treatment for patients with NTM diseases that do not respond to the antibiotics treatment. Here, we discuss the epidemiology, diagnosis, and treatment modalities available for TB and NTM diseases of humans.

1 November 2016 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
AUAmeeruddin Nusrath Unissa
Ameeruddin Nusrath Unissa
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
LHLuke Elizabeth Hanna
Luke Elizabeth Hanna
NSNagamiah Selvakumar
Nagamiah Selvakumar

16 June 2021 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
SRSanthamani Ramasamy
Santhamani Ramasamy
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a rapidly evolving pandemic worldwide with at least 68 million COVID-19-positive cases and a mortality rate of about 2.2%, as of 10 December 2020. In about 20% of COVID-19 instances, the disease exhibits moderate to severe symptoms.

21 June 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YKYing Kong
Ying Kong
HYHequan Yao
Hequan Yao
HRHongjun Ren
Hongjun Ren
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
SCSuat L. G. Cirillo
Suat L. G. Cirillo
JCJeffrey D Cirillo
Jeffrey D Cirillo
The slow growth rate and genetic intractability of tubercle bacilli has hindered progress toward understanding tuberculosis, one of the most frequent causes of death worldwide. We overcame this roadblock through development of near-infrared (NIR) fluorogenic substrates for β-lactamase, an enzyme expressed by tubercle bacilli, but not by their eukaryotic hosts, to allow real-time imaging of pulmonary infections and rapid quantification of bacteria in living animals by a strategy called reporter enzyme fluorescence (REF). This strategy has a detection limit of 6 ± 2 × 102colony-forming units (CFU) of bacteria with the NIR substrate CNIR5 in only 24 h of incubation in vitro, and as few as 104CFU in the lungs of live mice. REF can also be used to differentiate infected from uninfected macrophages by using confocal microscopy and fluorescence activated cell sorting.Mycobacterium tuberculosisand the bacillus Calmette–Guérin can be tracked directly in the lungs of living mice without sacrificing the animals. Therapeutic efficacy can also be evaluated through loss of REF signal within 24 h posttreatment by using in vitro whole-bacteria assays directly in living mice. We expect that rapid quantification of bacteria within tissues of a living host and in the laboratory is potentially transformative for tuberculosis virulence studies, evaluation of therapeutics, and efficacy of vaccine candidates. This is a unique use of an endogenous bacterial enzyme probe to detect and image tubercle bacilli that demonstrates REF is likely to be useful for the study of many bacterial infections.

30 April 2019 in mBio
Verified
Journal Article
Open access
PDF file
LSLanbo Shi
Lanbo Shi
QJQingkui Jiang
Qingkui Jiang
YBYuri Bushkin
Yuri Bushkin
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
STSanjay Tyagi
Sanjay Tyagi
Macrophages are the primary targets ofMycobacterium tuberculosisinfection; the early events of macrophage interaction withM. tuberculosisdefine subsequent progression and outcome of infection.M. tuberculosiscan alter the innate immunity of macrophages, resulting in suboptimal Th1 immunity, which contributes to the survival, persistence, and eventual dissemination of the pathogen.

26 May 2021 in Journal of Respiration
Verified
Journal Article
Open access
PDF file
Radha GopalaswamyRadha Gopalaswamy
Radha Gopalaswamy
ADAzger Dusthackeer
Azger Dusthackeer
SCSilambu Chelvi
Silambu Chelvi
Selvakumar SubbianSelvakumar Subbian
Selvakumar Subbian
Pathogenic Mycobacterium tuberculosis complex organisms (MTBC) primarily cause pulmonary tuberculosis (PTB); however, MTBC are also capable of causing disease in extrapulmonary (EP) organs, which pose a significant threat to human health worldwide. Extrapulmonary tuberculosis (EPTB) accounts for about 20–30% of all active TB cases and affects mainly children and adults with compromised immune systems. EPTB can occur through hematogenous, lymphatic, or localized bacillary dissemination from a primary source, such as PTB, and affects the brain, eye, mouth, tongue, lymph nodes of neck, spine, bones, muscles, skin, pleura, pericardium, gastrointestinal, peritoneum, and the genitourinary system as primary and/or disseminated disease. EPTB diagnosis involves clinical, radiological, microbiological, histopathological, biochemical/immunological, and molecular methods. However, only culture and molecular techniques are considered confirmatory to differentiate MTBC from any non-tuberculous mycobacteria (NTM) species. While EPTB due to MTBC responds to first-line anti-TB drugs (ATD), drug susceptibility profiling is an essential criterion for addressing drug-resistant EPTB cases (DR-EPTB). Besides antibiotics, adjuvant therapy with corticosteroids has also been used to treat specific EPTB cases. Occasionally, surgical intervention is recommended, mainly when organ damage is debilitating to the patient. Recent epidemiological studies show a striking increase in DR-EPTB cases ranging from 10–15% across various reports. As a neglected disease, significant developments in rapid and accurate diagnosis and better therapeutic interventions are urgently needed to control the emerging EPTB situation globally. In this review, we discuss the recent advances in the clinical diagnosis, treatment, and drug resistance of EPTB.